%0 Journal Article %T Significance of Inactivated Genes in Leukemia: Pathogenesis and Prognosis %J Cell Journal (Yakhteh) %I Royan Institute, Iranian Academic Center for Education Culture and Research (ACECR) %Z 2228-5806 %A Heidari, Nazanin %A Abroun, Saeid %A Bertacchini, essika %A Vosoughi, Tina Vosoughi %A Rahim, Fakher %A Saki, Najmaldin %D 2017 %\ 03/01/2017 %V 19 %N supplement 1 %P 9-26 %! Significance of Inactivated Genes in Leukemia: Pathogenesis and Prognosis %K Leukemia %K Gene silencing %K Tumor Suppressor %K pathogenesis %K Prognosis %R 10.22074/cellj.2017.4908 %X Epigenetic and genetic alterations are two mechanisms participating in leukemia, which caninactivate genes involved in leukemia pathogenesis or progression. The purpose of this reviewwas to introduce various inactivated genes and evaluate their possible role in leukemia pathogenesisand prognosis. By searching the mesh words “Gene, Silencing AND Leukemia” inPubMed website, relevant English articles dealt with human subjects as of 2000 were includedin this study. Gene inactivation in leukemia is largely mediated by promoter’s hypermethylationof gene involving in cellular functions such as cell cycle, apoptosis, and gene transcription.Inactivated genes, such as ASPP1, TP53, IKZF1 and P15, may correlate with poor prognosisin acute lymphoid leukemia (ALL), chronic lymphoid leukemia (CLL), chronic myelogenousleukemia (CML) and acute myeloid leukemia (AML), respectively. Gene inactivation may playa considerable role in leukemia pathogenesis and prognosis, which can be considered ascomplementary diagnostic tests to differentiate different leukemia types, determine leukemia prognosis, and also detect response to therapy. In general, this review showed some genes inactivated only in leukemia (with differences between B-ALL, T-ALL, CLL, AML and CML). These differences could be of interest as an additional tool to better categorize leukemia types. Furthermore; based on inactivated genes, a diverse classification of Leukemias could represent a powerful method to address a targeted therapy of the patients, in order to minimize side effects of conventional therapies and to enhance new drug strategies. %U https://www.celljournal.org/article_250930_f4328401ae192ef1fcf2a824665fa2bc.pdf